HeyJaredBen Fidler
- Indexed articles, last 90 days
- 4
- Latest publication
- Jul 30, 2026
- Outlet visibility, for yahoo.com
- Top 1K sites
- Earliest in this view
- Jul 7, 2026
Latest articles
Alnylam plunges as earnings deliver ‘one-two punch’ (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Alnylam Pharmaceuticals lost nearly 30% — or close to $12 billion — of its market value after the company surprised investors by lowering financial forecasts for its most important drug franchise by $200 million. The RNA-focused biotechnology company had previously predicted those drugs, the transthyretin amyloidosis medications Amvuttra and Onpattro,
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sarepta Therapeutics has found the leader it hopes can engineer a desperately needed turnaround. The company on Monday announced that Michael Severino, an executive with leadership experience at startups as well as large drugmakers, will become its next CEO effective July 28. He'll replace longtime leader Doug Ingram, who in February announced plans to
Scribe secures $129M in a rare gene editing IPO (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Scribe Therapeutics has raised close to $129 million in the first initial public offering for a developer of gene editing medicines in more than two years. The startup on Thursday sold 8.58 million shares at $15 apiece, topping projections set earlier this week. Shares will begin trading Friday on the Nasdaq stock exchange under the ticker symbol "SCTX
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs (opens the original)
Read excerpt
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vertex Pharmaceuticals is making the largest acquisition bet in its history, announcing late Monday an agreement to purchase a biotechnology company, Crinetics Pharmaceuticals, that recently brought to market a new kind of medicine for a rare hormonal disorder. Vertex is paying $85 per share in cash, or $10 billion overall, for Crinetics. The deal rank
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For yahoo.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.